Please login to the form below

Not currently logged in
Email:
Password:

Bausch & Lomb buys eye drop line

Bausch & Lomb buys Soothe eye drops from US-based Alimera Sciences for an undisclosed price and will extend the line

German ophthalmology company Bausch & Lomb (B&L) has bought the Soothe emollient (lubricant) eye drop line from US-based Alimera Sciences, a private ophthalmic pharmaceutical company.

B&L said it would expand the Soothe brand and establish a broader line of OTC products to relieve dry eye symptoms. The company will initially focus on two technologies, each designed to target a different layer of the tear film.

Financial details were undisclosed at the time of writing.

The Soothe deal follows B&L's December 2006 purchase of Alimera's OTC allergy franchise, including Alaway (ketotifen) antihistamine eye drops indicated for up to 12 hours of relief for itchy eyes due to ragweed, pollen, grass and animal hair.

Alimera's divestiture of its OTC portfolio marks its new focus on improving the delivery of fluocinolone through the in-licensing of Australia-based pSivida's Medidur drug delivery technology. Alimera and pSivida have a worldwide agreement to co-develop and market fluocinolone in Medidur to treat Diabetic Macular Edema (DME). In April 2007, both firms announced that phase III global clinical trial enrolment for Medidur had exceeded 500 patients.

B&L is currently mulling takeover bids by Warburg Pincus and Advanced Medical Optics (AMO). The company has expressed doubt that AMOís shareholders will approve the USD 4.2bn offer, while Warburg Pincusí USD 4.5bn bid, which includes around USD 830m of debt, remains the front runner.

1st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics